A
Achieve Life Sciences, Inc. (ACHV)
2.65
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
2.65
0.00 (0.00%)
Achieve Life Sciences, Inc., kechki bosqichdagi farmatsevtika kompaniyasi bo'lib, Kanadada, Qo'shma Shtatlarda va Buyuk Britaniyada nikotinga qaramlikdan xalos bo'lish uchun sitiziniklinni ishlab chiqadi va tijoratlashtiradi. Kompaniya miyadagi nikotin retseptorlari bilan o'zaro ta'sir qiluvchi, nikotinni tashlash alomatlarining og'irligini kamaytiradigan o'simlik asosidagi alkaloid bo'lgan sitiziniklinni taklif etadi. Uning Sopharma AD va Bristol universiteti bilan litsenziya va ta'minot shartnomasi mavjud. Achieve Life Sciences, Inc., shtab-kvartirasi Vashington shtatining Bothell shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Mark L. Rubinstein M.D. | Chief Medical Officer |
| Dr. Richard A. B. Stewart | President, CEO & Executive Director |
| Mr. Craig Donnelly | Chief Operations Officer |
| Mr. Mark K. Oki CPA | Chief Financial Officer |
| Ms. Nicole P. Jones | Vice President of Strategic Communications & Stakeholder Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-23 | S-3 | achv-20260123.htm |
| 2025-11-06 | 10-Q | achv-20250930.htm |
| 2025-10-07 | 8-K | achv-20251006.htm |
| 2025-09-11 | 8-K | achv-20250905.htm |
| 2025-08-07 | 10-Q | achv-20250630.htm |
| 2025-06-27 | 8-K | achv-20250626.htm |
| 2025-06-06 | 8-K | achv-20250604.htm |
| 2025-05-13 | 8-K | achv-20250513.htm |
| 2025-04-28 | ARS | 2025_ars_10k.pdf |
| 2025-03-11 | 8-K | achv-20250311.htm |